TSE:ARZ - Aralez Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
C$0.49 +0.49 (+Infinity)
(As of 05/27/2018 04:00 AM ET)
Previous CloseC$0.49
Today's RangeC$0.48 - C$0.51
52-Week RangeC$0.47 - C$3.72
Volume102,600 shs
Average Volume72,628 shs
Market CapitalizationC$119.34 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Aralez Pharmaceuticals (TSE:ARZ)

Aralez Pharmaceuticals logoAralez Pharmaceuticals Inc. operates as a specialty pharmaceutical company in the United States and Canada. It engages in acquiring, developing, and commercializing products in the areas of cardiovascular, pain management, dermatological allergy, and other indications. It offers Zontivity for the reduction of thrombotic cardiovascular events in patients with heart attack or peripheral arterial disease; Toprol-XL, a cardioselective beta-blocker that is indicated for the treatment of hypertension; Fibricor, a fenofibric acid for the treatment of severe hypertriglyceridemia and patients with primary hypercholesterolemia or mixed dyslipidemia; and Blexten, an antihistamine drug for the symptomatic relief of allergic rhinitis and chronic spontaneous urticarial. The company also markets Cambia, a non-steroidal anti-inflammatory drug (NSAID) for the acute treatment of migraine attacks; Soriatane for the treatment of severe psoriasis and other disorders of keratinization; Proferrin, an iron supplement; Fiorinal and Fiorinal C for the relief of tension type headaches; and Bezalip SR, a pan-peroxisome proliferator-activated receptor activator to treat hyperlipidemia, as well as to increase insulin sensitivity and decrease blood glucose levels for the patients with metabolic syndrome. In addition, it provides out-licensed products, which include VIMOVO for the relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, as well as to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers; and Treximet, a migraine medicine. The company was incorporated in 2015 and is headquartered in Mississauga, Canada.

Receive ARZ News and Ratings via Email

Sign-up to receive the latest news and ratings for ARZ and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Gold
Sub-IndustryN/A
SectorBasic Materials
SymbolTSE:ARZ
CUSIPN/A
Phone+1-905-8761118

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-100.42%
Return on Equity-146.16%
Return on Assets-20.43%

Miscellaneous

EmployeesN/A
Outstanding Shares67,011,000

Aralez Pharmaceuticals (TSE:ARZ) Frequently Asked Questions

What is Aralez Pharmaceuticals' stock symbol?

Aralez Pharmaceuticals trades on the Toronto Stock Exchange (TSX) under the ticker symbol "ARZ."

How were Aralez Pharmaceuticals' earnings last quarter?

Aralez Pharmaceuticals (TSE:ARZ) announced its earnings results on Tuesday, March, 13th. The company reported ($0.48) EPS for the quarter, missing analysts' consensus estimates of ($0.43) by $0.05. The business had revenue of $35.59 million for the quarter, compared to the consensus estimate of $32.38 million. Aralez Pharmaceuticals had a negative net margin of 100.42% and a negative return on equity of 146.16%. View Aralez Pharmaceuticals' Earnings History.

When is Aralez Pharmaceuticals' next earnings date?

Aralez Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, August, 8th 2018. View Earnings Estimates for Aralez Pharmaceuticals.

Who are some of Aralez Pharmaceuticals' key competitors?

Who are Aralez Pharmaceuticals' key executives?

Aralez Pharmaceuticals' management team includes the folowing people:
  • Mr. Adrian Adams, CEO & Director (Age 67)
  • Mr. Andrew I. Koven, Pres & Chief Bus. Officer (Age 60)
  • Dr. James Patrick Tursi, Chief Medical Officer (Age 53)
  • Mr. Michael Kaseta, CFO & Corp. Controller
  • Mr. John E. Barnhardt CPA, Principal Accounting Officer and VP of Fin. & Admin. (Age 68)

Has Aralez Pharmaceuticals been receiving favorable news coverage?

Media coverage about ARZ stock has been trending somewhat positive recently, Accern reports. The research firm identifies positive and negative news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Aralez Pharmaceuticals earned a coverage optimism score of 0.13 on Accern's scale. They also assigned media stories about the company an impact score of 46.77 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.

How do I buy shares of Aralez Pharmaceuticals?

Shares of ARZ and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is Aralez Pharmaceuticals' stock price today?

One share of ARZ stock can currently be purchased for approximately C$0.49.

How big of a company is Aralez Pharmaceuticals?

Aralez Pharmaceuticals has a market capitalization of C$119.34 million.

How can I contact Aralez Pharmaceuticals?

Aralez Pharmaceuticals' mailing address is 7100 West Credit Ave Suite 101, MISSISSAUGA, ON L5N 0E4, Canada. The company can be reached via phone at +1-905-8761118.


MarketBeat Community Rating for Aralez Pharmaceuticals (ARZ)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  51 (Vote Outperform)
Underperform Votes:  79 (Vote Underperform)
Total Votes:  130
MarketBeat's community ratings are surveys of what our community members think about Aralez Pharmaceuticals and other stocks. Vote "Outperform" if you believe ARZ will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARZ will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Aralez Pharmaceuticals (TSE:ARZ) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
2 Wall Street analysts have issued ratings and price targets for Aralez Pharmaceuticals in the last 12 months. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.502.673.003.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/AN/AN/A
Price Target Upside: N/AN/AN/AN/A

Aralez Pharmaceuticals (TSE:ARZ) Consensus Price Target History

Price Target History for Aralez Pharmaceuticals (TSE:ARZ)

Aralez Pharmaceuticals (TSE:ARZ) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
3/14/2018Bloom BurtonDowngradeBuy ➝ AccumulateView Rating Details
2/5/2018HC WainwrightReiterated RatingBuyView Rating Details
5/17/2017Chardan CapitalReiterated RatingBuyView Rating Details
(Data available from 5/27/2016 forward)

Earnings

Aralez Pharmaceuticals (TSE:ARZ) Earnings History and Estimates Chart

Earnings by Quarter for Aralez Pharmaceuticals (TSE:ARZ)

Aralez Pharmaceuticals (TSE:ARZ) Earnings Estimates

2018 EPS Consensus Estimate: ($0.88)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.33)($0.33)($0.33)
Q2 20181($0.31)($0.31)($0.31)
Q3 20181($0.15)($0.15)($0.15)
Q4 20181($0.09)($0.09)($0.09)

Aralez Pharmaceuticals (TSE ARZ) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/8/2018        
3/13/2018Q4 2017C($0.43)C($0.48)C$32.38 millionC$35.59 millionViewN/AView Earnings Details
11/9/2017Q3 2017C($0.50)C($0.46)C$29.81 millionC$30.53 millionViewN/AView Earnings Details
8/9/2017Q2 2017C($0.54)C($0.57)C$27.84 millionC$37.16 millionViewN/AView Earnings Details
5/9/2017Q1 2017C($0.43)C($0.56)C$34.37 millionViewN/AView Earnings Details
3/13/2017Q4 2016C($0.48)C$26.71 millionViewN/AView Earnings Details
11/8/2016Q3 2016C($0.38)C$17.77 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Aralez Pharmaceuticals (TSE:ARZ) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Aralez Pharmaceuticals (TSE ARZ) Insider Trading and Institutional Ownership History

Insider Trading History for Aralez Pharmaceuticals (TSE:ARZ)

Aralez Pharmaceuticals (TSE ARZ) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/14/2018James Patrick TursiInsiderSell5,948C$0.52C$3,092.96
3/19/2018James Patrick TursiInsiderSell5,950C$1.70C$10,115.00
12/8/2017Arthur S KirschDirectorBuy3,600C$1.45C$5,220.00
10/2/2017James Patrick TursiInsiderSell9,960C$2.50C$24,900.00
7/28/2017Scott J CharlesInsiderSell10,804C$1.25C$13,505.00
6/23/2017Eric TrachtenbergInsiderSell7,720C$1.33C$10,267.60
6/15/2017Arthur S KirschDirectorBuy15,000C$1.15C$17,250.00
6/14/2017Arthur S KirschDirectorBuy50,000C$1.17C$58,500.00
6/5/2017Andrew KovenInsiderSell1,906C$1.28C$2,439.68
3/20/2017Andrew KovenInsiderSell7,025C$2.41C$16,930.25
3/15/2017James Patrick TursiInsiderBuy4,750C$2.11C$10,022.50
3/15/2017Seth RudnickDirectorBuy5,000C$2.37C$11,850.00
(Data available from 1/1/2013 forward)

Headlines

Aralez Pharmaceuticals (TSE ARZ) News Headlines

Source:
DateHeadline
Today’s Research Reports on Aurinia Pharmaceuticals, Knight Therapeutics, Aralez Pharmaceuticals and Microbix BiosystemsToday’s Research Reports on Aurinia Pharmaceuticals, Knight Therapeutics, Aralez Pharmaceuticals and Microbix Biosystems
finance.yahoo.com - May 25 at 9:07 AM
Zacks Investment Research Weighs in on Aralez Pharmaceuticals Q2 2018 Earnings (ARZ)Zacks Investment Research Weighs in on Aralez Pharmaceuticals' Q2 2018 Earnings (ARZ)
www.americanbankingnews.com - May 14 at 1:38 AM
Aralez Pharmaceuticals (ARZ) Releases Quarterly  Earnings ResultsAralez Pharmaceuticals (ARZ) Releases Quarterly Earnings Results
www.americanbankingnews.com - May 8 at 10:47 AM
Aralez Pharmaceuticals (ARZ) to Release Earnings on TuesdayAralez Pharmaceuticals (ARZ) to Release Earnings on Tuesday
www.americanbankingnews.com - May 1 at 11:46 AM
Will Aralez Pharmaceuticals Inc’s (TSE:ARZ) Earnings Grow In The Next Couple Of Years?Will Aralez Pharmaceuticals Inc’s (TSE:ARZ) Earnings Grow In The Next Couple Of Years?
finance.yahoo.com - March 27 at 4:32 PM
Aralez Pharmaceuticals (ARZ) Given Buy Rating at HC WainwrightAralez Pharmaceuticals (ARZ) Given Buy Rating at HC Wainwright
www.americanbankingnews.com - March 25 at 8:16 AM
Aralez Pharmaceuticals (ARZ) Insider James Patrick Tursi Sells 5,950 SharesAralez Pharmaceuticals (ARZ) Insider James Patrick Tursi Sells 5,950 Shares
www.americanbankingnews.com - March 21 at 8:16 PM
Aralez Pharmaceuticals Forecasted to Post FY2018 Earnings of ($0.91) Per Share (ARZ)Aralez Pharmaceuticals Forecasted to Post FY2018 Earnings of ($0.91) Per Share (ARZ)
www.americanbankingnews.com - March 21 at 9:24 AM
Brokers Offer Predictions for Aralez Pharmaceuticals Q1 2018 Earnings (ARZ)Brokers Offer Predictions for Aralez Pharmaceuticals' Q1 2018 Earnings (ARZ)
www.americanbankingnews.com - March 20 at 7:46 AM
ARLZ: Aralez Set for Strong Revenue Growth in 2018ARLZ: Aralez Set for Strong Revenue Growth in 2018
finance.yahoo.com - March 19 at 4:33 PM
Aralez Pharmaceuticals (ARZ) Downgraded to "Accumulate" at Bloom BurtonAralez Pharmaceuticals (ARZ) Downgraded to "Accumulate" at Bloom Burton
www.americanbankingnews.com - March 16 at 9:54 PM
Does Aralez Pharmaceuticals Inc’s (TSE:ARZ) CEO Salary Compared Well With Others?Does Aralez Pharmaceuticals Inc’s (TSE:ARZ) CEO Salary Compared Well With Others?
finance.yahoo.com - December 28 at 1:38 PM
Aralez Pharmaceuticals, Inc. :ARZ-CA: Earnings Analysis: Q3, 2017 By the Numbers : November 14, 2017Aralez Pharmaceuticals, Inc. :ARZ-CA: Earnings Analysis: Q3, 2017 By the Numbers : November 14, 2017
finance.yahoo.com - November 14 at 4:35 PM
ARLZ: Increasing Revenue Projections for 2018ARLZ: Increasing Revenue Projections for 2018
finance.yahoo.com - November 14 at 2:12 AM
Aralez Pharmaceuticals, Inc. – Value Analysis (TORONTO:ARZ) : November 6, 2017Aralez Pharmaceuticals, Inc. – Value Analysis (TORONTO:ARZ) : November 6, 2017
finance.yahoo.com - November 6 at 5:06 PM
Aralez Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ARZ-CA : November 3, 2017Aralez Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ARZ-CA : November 3, 2017
finance.yahoo.com - November 3 at 9:14 AM
Aralez Pharmaceuticals Inc (ARZ) to Release Quarterly Earnings on ThursdayAralez Pharmaceuticals Inc (ARZ) to Release Quarterly Earnings on Thursday
www.americanbankingnews.com - November 2 at 3:32 AM
Todays Research Reports on Crescita Therapeutics, Centric Health Corporation, Cipher Pharmaceuticals and Aralez PharmaceuticalsToday's Research Reports on Crescita Therapeutics, Centric Health Corporation, Cipher Pharmaceuticals and Aralez Pharmaceuticals
finance.yahoo.com - October 16 at 4:52 PM
Aralez Pharmaceuticals Inc (ARZ) Insider Sells C$24,900.00 in StockAralez Pharmaceuticals Inc (ARZ) Insider Sells C$24,900.00 in Stock
www.americanbankingnews.com - October 4 at 10:42 PM
Aralez Pharmaceuticals, Inc. :ARZ-CA: Earnings Analysis: Q2, 2017 By the Numbers : August 15, 2017Aralez Pharmaceuticals, Inc. :ARZ-CA: Earnings Analysis: Q2, 2017 By the Numbers : August 15, 2017
finance.yahoo.com - August 15 at 5:03 PM
Todays Research Reports on CanniMed Therapeutics Inc., Aralez Pharmaceuticals Inc., Fennec Pharmaceuticals Inc. and Immunovaccine Inc.Today's Research Reports on CanniMed Therapeutics Inc., Aralez Pharmaceuticals Inc., Fennec Pharmaceuticals Inc. and Immunovaccine Inc.
finance.yahoo.com - August 8 at 3:55 PM
Aralez Pharmaceuticals, Inc. :ARZ-CA: Earnings Analysis: Q1, 2017 By the Numbers : August 3, 2017Aralez Pharmaceuticals, Inc. :ARZ-CA: Earnings Analysis: Q1, 2017 By the Numbers : August 3, 2017
finance.yahoo.com - August 3 at 10:31 PM
Aralez Pharmaceuticals Inc (TSE:ARZ) Scheduled to Post Quarterly Earnings on WednesdayAralez Pharmaceuticals Inc (TSE:ARZ) Scheduled to Post Quarterly Earnings on Wednesday
www.americanbankingnews.com - August 2 at 7:36 AM
Insider Selling: Aralez Pharmaceuticals Inc (TSE:ARZ) Insider Sells 10,804 Shares of StockInsider Selling: Aralez Pharmaceuticals Inc (TSE:ARZ) Insider Sells 10,804 Shares of Stock
www.americanbankingnews.com - July 28 at 10:35 PM
Aralez To Report Second Quarter 2017 Financial Results On August 9, 2017Aralez To Report Second Quarter 2017 Financial Results On August 9, 2017
finance.yahoo.com - July 24 at 1:01 PM
Aralez Announces District Court Decision to Uphold VIMOVO (Naproxen/Esomeprazole Magnesium) Patents - PR Newswire (press release)Aralez Announces District Court Decision to Uphold VIMOVO (Naproxen/Esomeprazole Magnesium) Patents - PR Newswire (press release)
www.prnewswire.com - June 27 at 8:48 PM
Form 8-K Aralez Pharmaceuticals For: Jun 27Form 8-K Aralez Pharmaceuticals For: Jun 27
www.streetinsider.com - June 27 at 3:47 PM
Aralez Announces National US Commercial Launch Of Zontivity - PR Newswire (press release)Aralez Announces National US Commercial Launch Of Zontivity - PR Newswire (press release)
www.prnewswire.com - June 7 at 6:36 AM
Aralez Pharmaceuticals Inc. 2017 Q1 - Results - Earnings Call SlidesAralez Pharmaceuticals Inc. 2017 Q1 - Results - Earnings Call Slides
seekingalpha.com - May 11 at 4:05 PM
Aralez Announces Reduction In U.S. Sales Force And Cost Savings Program - PR Newswire (press release)Aralez Announces Reduction In U.S. Sales Force And Cost Savings Program - PR Newswire (press release)
www.prnewswire.com - April 7 at 8:07 AM
Horizon Pharma (HZNP) Granted Additional USPTO Notice of Allowance With Claims Covering VIMOVO Delayed ... - StreetInsider.comHorizon Pharma (HZNP) Granted Additional USPTO Notice of Allowance With Claims Covering VIMOVO Delayed ... - StreetInsider.com
www.streetinsider.com - March 31 at 3:46 PM
Aralez Reports Fourth Quarter And Full-Year 2016 Financial Results - PR Newswire (press release)Aralez Reports Fourth Quarter And Full-Year 2016 Financial Results - PR Newswire (press release)
www.prnewswire.com - March 13 at 3:45 PM
Aralez to Present at the RBC Capital Markets Global Healthcare Conference - PR Newswire (press release)Aralez to Present at the RBC Capital Markets Global Healthcare Conference - PR Newswire (press release)
www.prnewswire.com - February 16 at 3:42 PM
Aralez Provides Update on PBM Formulary Status for Yosprala - PR Newswire (press release)Aralez Provides Update on PBM Formulary Status for Yosprala - PR Newswire (press release)
www.prnewswire.com - December 15 at 3:16 PM
Aralez to Participate at Two Upcoming Healthcare Conferences - PR Newswire (press release)Aralez to Participate at Two Upcoming Healthcare Conferences - PR Newswire (press release)
www.prnewswire.com - November 30 at 9:31 AM
Aralez To Acquire US Rights To AstraZenecas Beta Blocker Toprol-XL For $175 MlnAralez To Acquire US Rights To AstraZeneca's Beta Blocker Toprol-XL For $175 Mln
www.nasdaq.com - October 4 at 3:33 PM
AZ agreement with Aralez for Toprol-XL in USAZ agreement with Aralez for Toprol-XL in US
globenewswire.com - October 4 at 3:33 PM
Aralez Pharmaceuticals Inc (ARLZ) Soars on AstraZeneca DealAralez Pharmaceuticals Inc (ARLZ) Soars on AstraZeneca Deal
investorplace.com - October 4 at 11:01 AM
AstraZeneca cuts Brilinta sales hopes on artery disease failureAstraZeneca cuts Brilinta sales hopes on artery disease failure
uk.finance.yahoo.com - October 4 at 8:23 AM
Aralez Pharmaceuticals Lead Drug Yosprala Approved By The FDAAralez Pharmaceuticals' Lead Drug Yosprala Approved By The FDA
seekingalpha.com - September 16 at 8:39 AM
Why Aralez Pharmaceuticals Inc Jumped Higher TodayWhy Aralez Pharmaceuticals Inc Jumped Higher Today
www.fool.com - August 1 at 4:36 PM

SEC Filings

Aralez Pharmaceuticals (TSE:ARZ) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

Aralez Pharmaceuticals (TSE ARZ) Stock Chart for Sunday, May, 27, 2018

Loading chart…

This page was last updated on 5/27/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.